HIV theranostic on track for 2000 submission:
This article was originally published in Clinica
The US FDA has told Canadian pharmacogenomics company Visible Genetics that it need not complete the clinical trial of its Trugene HIV-1 genotyping kit for directing the treatment of HIV infected individuals. However, Toronto-based Visible Genetics will be required to finish its proficiency trial, which is designed to demonstrate Trugene's quality, reliability, accuracy and reproducibility. Data from the proficiency trial, which should be completed by the end of 1999, will be submitted to the FDA in the first half of 2000 as part of its market approval application for the kit.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.